Recent Company News

• 10:57 AM ET Feb 11, 2026
  

  Transcript Intelligence: Akari Therapeutics at Webull Financial Corporate Connect Webinar Series Virtual Conference - Abizer Gaslightwala

• 11:30 AM ET Feb 09, 2026
  

  JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026

• 08:48 AM ET Jan 26, 2026
  

  Akari Therapeutics files key patent; unveils second ADC program AKTX-102 targeting CEACAM5 expressing solid Tumors ($0.27, 0.00)

• 09:03 AM ET Jan 09, 2026
  

  Akari Therapeutics CEO provides corporate update on the company's progress and path to clinical transition In 2026 ($0.28, 0.00)

• 05:26 PM ET Jan 05, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:54 AM ET Jan 05, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 07:17 AM ET Jan 05, 2026
  

  Akari Therapeutics initiated buy at Ladenburg Thalmann ($0.29, 0.00)

• 09:26 AM ET Dec 30, 2025
  

  Akari Therapeutics provides catalyst and milestone update in shareholder letter ($0.26, 0.00)

• 08:32 AM ET Dec 23, 2025
  

  Akari Therapeutics initiates GMP manufacturing of AKTX-101 program ($0.26, 0.00)

• 09:31 AM ET Dec 16, 2025
  

  Akari Therapeutics announces $5M financing, including concurrent registered direct offering and private placement priced at-market ($0.41, 0.00)